| Literature DB >> 32848052 |
Yuki Hirose1, Tomohiro Kitazono1, Maiko Sezaki1, Manabu Abe2, Kenji Sakimura2, Hiromasa Funato1,3, Hiroshi Handa4, Kaspar E Vogt1, Masashi Yanagisawa5,6,7,8.
Abstract
Thalidomide exerts its teratogenic and immunomodulatory effects by binding to cereblon (CRBN) and thereby inhibiting/modifying the CRBN-mediated ubiquitination pathway consisting of the Cullin4-DDB1-ROC1 E3 ligase complex. The mechanism of thalidomide's classical hypnotic effect remains largely unexplored, however. Here we examined whether CRBN is involved in the hypnotic effect of thalidomide by generating mice harboring a thalidomide-resistant mutant allele of Crbn (Crbn YW/AA knock-in mice). Thalidomide increased non-REM sleep time in Crbn YW/AA knock-in homozygotes and heterozygotes to a similar degree as seen in wild-type littermates. Thalidomide similarly depressed excitatory synaptic transmission in the cortical slices obtained from wild-type and Crbn YW/AA homozygous knock-in mice without affecting GABAergic inhibition. Thalidomide induced Fos expression in vasopressin-containing neurons of the supraoptic nucleus and reduced Fos expression in the tuberomammillary nuclei. Thus, thalidomide's hypnotic effect seems to share some downstream mechanisms with general anesthetics and GABAA-activating sedatives but does not involve the teratogenic CRBN-mediated ubiquitin/proteasome pathway.Entities:
Keywords: cereblon; electroencephalography/electromyography (EEG/EMG); mouse; sleep; supraoptic nucleus
Mesh:
Substances:
Year: 2020 PMID: 32848052 PMCID: PMC7502749 DOI: 10.1073/pnas.1917701117
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205